In HAE, we are advancing multiple drug candidates into Phase 1 clinical trials, with additional program candidates in preclinical development. Our most advanced candidate, KVD900, is in a Phase 2 clinical trial for on-demand treatment of HAE, with data from this trial expected in late 2019. In DME, our most advanced compound, an intravitreally administered plasma kallikrein inhibitor known as KVD001, has successfully completed its first-in-human study in patients with DME and began a Phase 2 clinical trial in 2017. We anticipate this trial to complete in the second half of 2019. In October 2017, we entered into a collaboration agreement with Merck for KVD001 as well as future oral DME compounds based upon plasma kallikrein inhibition.
We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.
Our offices and labs are in Cambridge, MA and Salisbury, UK.